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Abstract
 
Hepatic stem cells (oval cells) proliferate within the liver after exposure to a variety of hepatic
carcinogens and can generate both hepatocytes and bile duct cells. Oval cell proliferation is
commonly seen in the preneoplastic stages of liver carcinogenesis, often accompanied by an in-
flammatory response. Tumor necrosis factor (TNF), an inflammatory cytokine, is also impor-
tant in liver regeneration and hepatocellular growth. The experiments reported here explore
the relationship among the TNF inflammatory pathway, liver stem cell activation, and tumori-
genesis. We demonstrate that TNF is upregulated during oval cell proliferation induced by a
choline-deficient, ethionine-supplemented diet and that it is expressed by oval cells. In TNF
receptor type 1 knockout mice, oval cell proliferation is substantially impaired and tumorigen-
esis is reduced. Oval cell proliferation is impaired to a lesser extent in interleukin 6 knockout
mice and is unchanged in TNF receptor type 2 knockout mice. These findings demonstrate
that TNF signaling participates in the proliferation of oval cells during the preneoplastic phase
of liver carcinogenesis and that loss of signaling through the TNF receptor type 1 reduces the
incidence of tumor formation. The TNF inflammatory pathway may be a target for therapeutic
intervention during the early stages of liver carcinogenesis.
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Introduction
 
Hepatocytes, the main cellular component of the liver, are
highly differentiated cells that retain the capacity to prolif-
erate. In the normal liver, hepatocytes are metabolically ac-
tive but rarely divide. However, when cell or tissue deficits
are imposed on the liver by tissue resection (partial hepa-
tectomy) or acute chemical injury (carbon tetrachloride
poisoning being the most common example), almost all
hepatocytes proliferate to correct the deficit. Recent exper-
iments involving the repopulation of damaged mouse livers
by hepatocyte transplantation as well as serial hepatocyte
transplantation have demonstrated that these cells have a
remarkable proliferative capacity (1, 2).
Despite these observations, a large number of studies
make it clear that the adult liver also contains a progenitor
or stem cell compartment (for review see references 3 and
4). These cells, thought to be located at the canals of Her-
ing (structures that connect hepatocyte biliary canaliculi
with the bile duct system) have epithelial morphology but
differ from small hepatocytes or bile duct cells (5, 6). Al-
though the definitions may not be entirely accurate, we
will use the term “stem cell” to refer to canals of Hering
cells capable of generating lineage (6).
 
Stem cells are activated under conditions of liver injury
in which hepatocytes cannot perform their regenerative
functions. Under these circumstances, they give rise to the
oval cells, a heterogeneous, proliferative cell population
capable of differentiating into hepatocytes and cells of the
biliary system (7–10). Recent data suggest that oval cells as
well as hepatocytes can be generated from bone marrow
 
cells (11, 12). Oval cells express 
 
a
 
-fetoprotein (AFP),
 
1
 
 a
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marker of fetal hepatocytes, and fetal and adult isozymes of
aldolase and pyruvate kinase as well as phenotypic features
of bile duct cells, such as expression of cytokeratins 7 and
19 (CK7 and CK19) and surface antigens including A6
and G7 (for review see references 13 and 14). Proliferation
of oval cells in rodents occurs after induction of liver in-
jury with a variety of agents. In these situations, oval cells
may generate hepatocytes that repopulate damaged liver
(8, 15–20). However, as oval cells may be targets for car-
cinogens, oval cells may also function as tumor progenitors
through the generation of abnormal hepatocytes. Particu-
larly well studied are oval cell proliferation and differentia-
tion models induced by 2-acetylamino fluorene and partial
hepatectomy (7, 21), dipin and partial hepatectomy (9),
administration of chemicals such as galactosamine and ret-
rorsine (17, 22), azo dye carcinogens (15, 23), and feeding
rats a choline-deficient, ethionine-supplemented (CDE)
diet (24, 25). Oval cells have also been identified in hu-
man livers in a variety of conditions, including chronic
liver diseases that may be associated with acute liver failure
(6, 26).
Understanding the mechanisms by which liver progeni-
tor cells can repopulate the liver or give rise to tumors is of
fundamental importance. Several potentially important oval
cell growth factors have been identified, including hepato-
cyte growth factor, transforming growth factor 
 
a
 
, epider-
mal growth factor, stem cell factor, fibroblast growth fac-
tor, leukemia inhibitory factor, and IFN-
 
g
 
 (27–33).
Whether these factors are required for proliferation, migra-
tion, and/or differentiation of the oval cell compartment is
not known. Nagy et al
 
.
 
 (34) reported that dexamethasone
inhibits oval cell proliferation in the 2-acetylamino fluo-
rene and partial hepatectomy model, an effect that is prob-
ably mediated through glucocorticoid inhibition of nuclear
factor (NF)-
 
k
 
B activation (35), an important downstream
component of the TNF receptor type 1 (TNF R1) signal-
ing pathway. In this context, it is of interest that although
oval cell proliferation commonly occurs when hepatocytes
are not capable of responding to a growth stimulus, oval
cells are not detected in livers of mice lacking TNF R1 in
which hepatocyte replication is deficient after partial hepa-
tectomy or carbon tetrachloride injury (36–38). These ob-
servations suggest that signaling through TNF R1 might be
important for oval cell proliferation.
Kirillova et al. (39) have recently shown that TNF stim-
ulates the proliferation of oval cells in culture (LE-6 cell
line) and acts through the activation of NF-
 
k
 
B. The studies
presented in this paper are designed to determine whether
oval cell proliferation in the liver in vivo
 
 
 
requires TNF sig-
naling. For these experiments, the rat CDE diet model of
oval cell proliferation and carcinogenesis was adapted for
mice to permit the use of animals with the appropriate tar-
geted mutations. The results show that deficiency of TNF
R1, but not TNF R2, inhibits the oval cell response as well
as tumor development in the livers of mice receiving a car-
cinogenic diet.
 
Materials and Methods
 
Animals
 
Mice of two strains were used in this study. For the evaluation
of TNF-
 
a
 
 levels, wild-type (WT) BDF-1 strain mice (purchased
from Animal Resources Centre) were used. Knockout (KO)
mice were of the C57BL/6 strain. TNF R2 KO mice were bred
into the C57BL/6 lineage by backcrossing (37). WT C57BL/6
and IL-6 KO mice were purchased from The Jackson Laboratory.
TNF R1 KO mice bred in the laboratory were also used (36–38,
40, 41). Animals were housed in temperature-controlled rooms
with alternating 12-h light and dark cycles. Animal experiments
were performed in accordance with the guidelines of the Univer-
sity of Washington School of Medicine or the National Health
and Medical Research Council of Australia.
 
Dietary Conditions.
 
4-wk-old male mice were administered a
diet consisting of normal laboratory chow and drinking water
(control), 100% choline-deficient chow (ICN Biomedicals) and
drinking water supplemented with 0.165% (wt/vol) ethionine
(ICN Biomedicals) (100% CDE diet), or a 1:1 mixture of cho-
line-deficient and normal chow and drinking water supple-
mented with 0.15% ethionine (50% CDE diet).
 
Liver Damage Assessment.
 
For assessment of liver damage,
blood samples from duplicate WT, TNF R1 KO, TNF R2 KO,
and IL-6 KO mice after 2, 3, or 4 wk of 50% CDE feeding were
analyzed for alanine aminotransferases by the University of Wash-
ington Veterinary Service. Averaged levels for duplicate KO
mice were expressed as a percentage of WT mice at each time
point.
 
Cell Isolations
 
Livers were dissociated by a three-step collagenase perfusion
via the hepatic portal vein modified from the method of Seglen et
al. (42). In brief, livers were perfused at a rate of 2–3 ml/min, first
with perfusion buffer (KCl [0.4 g/liter]/NaCl [6.8 g/liter]/
HEPES [4.8 g/liter]/ NaHCO
 
3
 
 [2.1 g/liter]/glucose [1 g/liter])
containing 0.63 mM EGTA (50 ml), then with perfusion buffer
alone (25 ml), and finally with perfusion buffer containing 5.1
mM CaCl
 
2
 
 and 6 U type H collagenase (75 ml; Roche). For
hepatocyte isolation, dissociated liver was dispersed in Leibowitz
(L15) medium (GIBCO BRL), and hepatocytes were purified by
filtration and centrifugation as described by Seglen et al. (42). For
oval and inflammatory cell isolation, dissociated livers were incu-
bated (25 min, 37
 
8
 
C) with shaking in Joklik medium (GIBCO
BRL) containing 10.25 U type VIII collagenase (Sigma-Aldrich)
and 0.002% DNase I (Sigma-Aldrich). Cells were filtered
through gauze (45 
 
m
 
m) and centrifuged (270 
 
g
 
) between and after
treatments to remove debris. Cell pellets were then washed and
resuspended in Joklik medium containing 10% FCS (GIBCO
BRL) and 0.0045% DNase I. Cells were then fractionated by
centrifugal elutriation using a Beckman JE6B rotor (Beckman
Coulter) at 1,206 
 
g
 
 as described by Yaswen et al
 
. 
 
(25). Inflamma-
tory cells were eliminated from the oval cell fraction (collected
at 40 ml/min) using a MiniMACS™ MS
 
1
 
 separation system
(Miltenyi Biotec) with an anti-CD45 bead conjugate (Miltenyi
Biotec) according to the manufacturer’s instructions. CD45
 
1
 
 in-
flammatory cells were also collected once oval cells were purified.
Cell cytospins were stained for inflammatory cells using a cocktail
of antibodies (directed against CD4, CD8, CD3, B220, J11d,
Mac-1, and F4-80), and positive cells were counted in a fixed
area. Phase contrast illumination was used to assess the total num- 
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ber of cells in the same area. The percentage of inflammatory cells
in the oval cell fraction was estimated based on the average of
eight areas of cells.
 
Analysis of TNF-
 
a
 
 mRNA Expression
 
Total RNA was isolated from whole liver (100 mg) or purified
cells (5 
 
3 
 
10
 
6
 
) using TRIZOL RNA isolation reagent (Life
Technologies) according to the manufacturer’s instructions and
quantitated using spectrophotometry. Expression of TNF-
 
a
 
mRNA levels was determined from 5–20 
 
m
 
g of total RNA using
RiboQuant™ RNase Protection assay with the mCK-3 template
set (BD PharMingen) according to the manufacturer’s instruc-
tions. Bands were visualized using a BAS-1000 PhosphorImager
(Fuji) and quantified by densitometry. TNF-
 
a
 
 levels were nor-
malized to glyceraldehyde 3 phosphate dehydrogenase (GAPDH)
to account for loading differences between lanes.
 
Histology and Immunohistochemistry
 
Portions of liver tissue (5 mm
 
3
 
) were immerse fixed in Car-
noy’s fixative for 2 h and then processed and paraffin embedded.
Portions (10 
 
3
 
 10 
 
3
 
 2 mm) were also snap frozen for cryostat
sectioning. 5-
 
m
 
m paraffin or 10-
 
m
 
m cryostat sections (post-fixed
at 4
 
8
 
C in 1:1 methanol/acetone) were immunohistochemically
stained for M
 
2 
 
pyruvate kinase (M
 
2
 
PK; diluted 1:500; Schebo
Technologies), CK19 (diluted 1:10; Amersham Pharmacia Bio-
tech), A6 (reference 43; diluted 1:10; a gift from Dr. V. Factor,
National Cancer Institute, Bethesda, MD), AFP (diluted 1:500;
ICN Biochemicals), or proliferating cell nuclear antigen (PCNA;
diluted 1:50; Leinco Technologies) using a two- (A6, CK19,
PCNA, AFP) or three-step (M
 
2
 
PK) indirect method. Peroxidase
activity was detected using Liquid DAB (Dako).
 
Cell Scores
 
Oval cells were identified as small, oval-shaped cells with scant
cytoplasm that stained positively for M
 
2
 
PK or CK19. Proliferat-
ing oval cells were scored as cells bearing the morphology of oval
cells (as determined by hematoxylin counterstain) that expressed
PCNA in their nuclei. Care was taken to exclude round inflam-
matory cells, elongated endothelial cells, and larger hepatocytes.
Inflammatory cells were identified using two-step immunohis-
tochemistry with a cocktail of antibodies directed against CD4,
CD8, and J11d.
For each section for a given mouse, 10 areas were scored using
a 40
 
3
 
 objective, and the number of oval cells was normalized to
that of hepatocytes. Averages for the 10 areas were determined
and then pooled for 5 experiments, and the overall average and
standard error of the mean calculated. Oval cell numbers between
mouse types were compared using Student’s 
 
t
 
 test.
 
Pathological Assessment of Carcinogenesis
 
Liver sections from long-term CDE mice were examined in-
dependently without knowledge of genotype by two groups of
scientists (G. Yeoh and B. Knight; N. Fausto and J. Rhim) and
scored for evidence of fibrosis, dysplasia, and neoplasia. Multiple
(four to five) samples of liver from each animal were used for
evaluations. Data on tumor incidence between genotypes was
analysed using a one-tailed analysis of variance test.
 
Results
 
TNF-
 
a
 
 Expression Is Associated with Oval Cell Prolifera-
tion.
 
TNF-
 
a
 
 expression was evaluated in mice fed a 100%
CDE diet. A short-term study showed that TNF mRNA is
rapidly induced 1 d after administration of the diet and
continues to increase during the next 2 d (Fig. 1 A). Longer
term feeding of the CDE diet caused increases in TNF
mRNA of four- to sevenfold above those of mice main-
tained on the normal diet. A representative autoradiograph
for this experiment is shown, along with quantitation data
pooled from six experimental animals. (Fig. 1 B). To deter-
mine which cells express TNF-
 
a
 
 mRNA, ribonuclease
protection analysis was performed on RNA extracted from
hepatocytes and oval and inflammatory cells isolated from
mice that received the CDE diet for 3 wk. Inflammatory
cell contamination in the oval cell fraction was determined
to be 0.96 
 
6 
 
0.25%. Strong expression of TNF-
 
a
 
 mRNA
was detected in oval and inflammatory cells, but not hepa-
tocytes (Fig. 1 C). These results demonstrate that the feed-
ing of the carcinogenic diet leads to a rapid and persistent
increase in TNF in the liver, mostly due to oval cells and
inflammatory cells that invade the liver.
Figure 1. Increased expression of
TNF-a during CDE diet feeding.
TNF-a levels were detected by ribo-
nuclease protection assay and quanti-
fied by densitometry relative to
GAPDH. TNF levels increased during
the first few days of the CDE diet (A).
A peak in TNF-a expression in CDE
samples (gray bars) compared with WT
(white bars) was seen at 2 wk (B). Re-
peat experiments show the result illus-
trated in the representative autoradio-
graph to be reproducible (bars represent mean 6 SEM, n 5 6). Analysis of TNF-a mRNA in purified cell types showed expression in oval (OC) and
inflammatory (IC) cells but not in hepatocytes (H) (C). 
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Oval Cell Response Is Deficient in Mice Lacking TNF R1.
 
A comparison between WT and TNF R1 KO mice fed a
50% CDE diet revealed that the oval cell response was di-
minished in TNF R1 KO mice (Fig. 2). This is evident
from histological examination of liver sections from WT
(Fig. 2 A) and TNF R1 KO (Fig. 2 B) mice. Immunohis-
tochemistry showed that the attenuated oval cell response in
TNF R1 KO mice could be demonstrated regardless of the
oval cell marker used. Staining for CK19 (Fig. 2, C and D)
and A6 (Fig. 2, E and F) both show fewer oval cells in TNF
R1 KO (Fig. 2, D and F) than WT (Fig. 2, C and E) mice.
 
We used two markers to estimate the number of oval
cells present in the livers of mice fed the carcinogenic diet:
CK19 and M
 
2
 
PK, the fetal liver isozyme of pyruvate ki-
nase. The absolute numbers of oval cells scored based on
CK19 or M
 
2
 
PK staining differed (cell counts based on
M
 
2
 
PK were 
 
z
 
30% lower than those estimated by CK19
staining). This is not surprising, as CK19 stains mature bile
duct cells as well as oval cells. Nevertheless, the relative
comparison of oval cell numbers between WT and TNF
R1 KO mice using each of these markers was not signifi-
cantly different (Chi-squared analysis, 
 
P
 
 
 
.
 
 0.01). In these
Figure 2. Diminished oval cell
response in TNFR1 KO mice.
Hematoxylin and eosin staining
of livers after 2 wk of CDE diet
shows a decreased oval cell re-
sponse in TNF R1 KO com-
pared with WT mice (A and B).
Immunohistochemistry for
CK19 (C and D) and A6 (E and
F) after 2 wk of CDE diet in
WT (C and E) and TNF R1 KO
(D and F) highlights the reduced
oval cell numbers in TNF R1
KO mice. By contrast, A6 stain-
ing in TNF R2 KO (G) shows
no difference from WT. A6-pos-
itive oval cells in IL-6 KO mice
(H) are more abundant than in
TNF R1 KO (compare with F).
Bar 5 60 mM. 
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studies, M
 
2
 
PK was used to quantitate oval cell numbers.
This marker was considered superior, as it can be used on
paraffin sections, allowing cell counts to be performed
based on both staining and morphology. Furthermore, un-
like CK19, it discriminates between oval and biliary cells
and, unlike A6, has commercially available antibodies. Re-
sults show that TNF R1 KO mice have, on average, 50%
fewer oval cells than WT after the same dietary treatment
(Fig. 3 A). This difference was found to be of statistical sig-
nificance at all time points (
 
P
 
 
 
,
 
 0.01). Thus, the oval cell
response after the feeding of a carcinogenic diet is deficient
in mice that lack TNF R1.
To determine the extent of oval cell proliferation in WT
and KO mice fed the CDE diet, we counted the number of
proliferating oval cells using PCNA as a marker. A defi-
ciency in oval cell proliferation in TNF R1 KO mice was
evident. Numbers of PCNA-positive oval cells in TNF R1
KO mice were, on average, only 28% of WT (Fig. 3 B), a
significant difference at all time points (
 
P
 
 
 
, 
 
0.01).
 
Analysis of Oval Cell Response in TNF R2 and IL-6 KO
Mice.
 
Although TNF R2 is not essential for initiation of
liver regeneration and hepatocyte proliferation after partial
hepatectomy, it participates in the transduction of TNF sig-
nals in the liver (37). To examine the importance of TNF
R2 signaling in the oval cell response, we determined
whether the response to a 50% CDE diet is altered in TNF
R2 KO mice. Immunohistochemistry for A6, an oval cell
surface antigen, shows no difference between TNF R2 KO
and WT mice after the same dietary treatment (Fig. 2 G).
This is reflected in the number of oval cells quantitated by
M
 
2
 
PK staining (Fig. 3 A). Oval cell proliferation, deter-
mined by PCNA staining, was also not impaired in TNF
R2 KO mice (Fig. 3 B). All comparisons between WT and
TNF R2 KO revealed no significant difference between
genotypes (
 
P
 
 
 
.
 
 0.1).
The TNF R1 signaling pathway activated after partial
hepatectomy involves the downstream activation of IL-6
(36, 37). KO mice deficient in IL-6 have impaired liver re-
generation (44). In addition, IL-6 has been shown to be a
mitogen for bile duct cells (45, 46). Based on these obser-
vations, we evaluated whether the oval cell response is al-
tered in IL-6 KO mice. A small but consistent reduction in
oval cell numbers in IL-6 KO mice fed the CDE diet was
apparent from sections stained for A6 (Fig. 2 H). This was
confirmed by quantitation of oval cell numbers; IL-6 KO
mice had, on average, a 30% reduction in M
 
2
 
PK-positive
and a 50% reduction in PCNA-positive oval cells (Fig. 3, A
and B). Statistical evaluation of the data revealed no signifi-
cant difference between WT and IL-6 KO for M
 
2
 
PK-posi-
tive cells at all time points (
 
P
 
 
 
.
 
 0.05) and a significant dif-
ference in PCNA-positive oval cell counts only at 3 wk of
dietary treatment (
 
P
 
 
 
,
 
 0.05). Cell counts differed with
some significance between IL-6 KO and TNF R1 KO at 3
(
 
P
 
 
 
,
 
 0.05) and 4 wk (
 
P
 
 
 
,
 
 0.07), but not 2 wk (
 
P
 
 
 
.
 
 0.1).
 
Assessment of Liver Damage. It could be argued that
TNF R1 KO mice had a diminished oval cell response be-
cause the lack of signaling through TNF R1 might protect
them from liver damage that stimulates oval cell produc-
tion. To examine this possibility, we measured serum ala-
nine aminotransferase (ALT) levels in WT, TNF R1, TNF
R2, and IL-6 KO mice maintained on a 50% CDE diet for
2–4 wk (Fig. 4). ALT activity was, on average, 87, 96, and
65% of WT levels for TNF R1, TNF R2, and IL-6 KO
mice (not significant; P . 0.05). Fat accumulation after 3
Figure 3. Quantitation of oval cell numbers in WT and KO mice. Liv-
ers were stained using either M2PK (for specific detection of oval cells) or
PCNA (to detect proliferating cells), and positive oval cells were scored
and normalized to hepatocyte number in the same area. Results shown
are WT (white bars), TNF R2 KO (dark gray bars), TNF R1 KO (black
bars), and IL-6 KO (light gray bars). Results are expressed as mean 6
SEM, n 5 5 (WT, TNF R1 KO, TNF R2 KO) or mean 1 range, n 5 2
(IL-6 KO). Both M2PK- (A) and PCNA-based (B) oval cell counts reflect
the pattern of oval cell response documented in Fig. 2.
Figure 4. Assessment of liver damage in KO mice. Serum from dupli-
cate mice were analyzed for ALT activity and the results expressed as
mean 1 range. Results shown are WT (white bars), TNF R2 KO (dark
gray bars), TNF R1 KO (black bars), or IL-6 KO (light gray bars). There
is no difference between genotypes at any time point in the experiment.1814 Tumor Necrosis Factor Signaling in Liver Carcinogenesis
or 4 wk of CDE feeding was present in some of the livers.
The extent of steatosis varied from animal to animal, but
no difference between genotypes was observed in fat accu-
mulation. Inflammatory cell infiltration, which often ac-
companies oval cell proliferation (47), was observed in all
livers. The distribution of inflammatory cells (detected by
CD8, CD4, and J11D antibodies) did not differ between
animal types, indicating that the inflammatory response is
not diminished in the KO mice (data not shown).
Liver Tumor Incidence Is Reduced in TNF R1 KO Mice.
Prolonged feeding of the CDE diet to rats causes the devel-
opment of liver tumors after 10–12 mo (48, 49). There has
been much debate over the relationship between oval cell
proliferation and liver tumor development in models of
hepatocarcinogenesis in which oval cell proliferation is
prominent. It has been assumed that oval cells, either di-
rectly or indirectly through the generation of hepatocytes,
function as tumor progenitors. Because the oval cell re-
sponse is impaired in TNF R1 KO mice, it was of interest
to determine whether carcinogenesis in these animals
would also be inhibited. To test this hypothesis, WT and
TNF R1 KO mice were fed a 50% CDE diet for z9 mo.
Of eight WT mice killed at 36 wk, five had well developed
tumors, one had hepatic dysplasia and only neoplastic foci,
and two had histologically normal livers. In contrast, only
one in seven TNF R1 KO mice fed the CDE diet had well
developed liver tumors, while four had normal livers and
two had evidence of dysplasia and early neoplastic foci. Tu-
mor incidence in WT mice was found to be significantly
greater than in TNF R1 KO by analysis of variance (P ,
0.05). Tumors ranged from 2 to 8 mm in diameter. Multi-
ple nodules were seen in four animals (four to seven nod-
ules per animal); nodules were distributed over all liver
lobes.
All livers examined showed some disruption, and steato-
sis was evident in most. The extent of fat accumulation
varied from animal to animal but did not correlate with
genotype. Additionally, evaluation of liver to body weight
ratios revealed a small but significant (P 5 0.05) elevation
in liver weight in TNF R1 KO animals after long-term
diet feeding (data not shown). Hematoxylin and eosin
staining shows steatosis in both mice, with tumor nodules
evident in WT but not TNF R1 KO (Fig. 5, A and B).
Staining of long-term–exposed CDE livers for AFP, a liver
tumor cell marker, showed strong expression in nodular ar-
eas of hepatocytes in WT (Fig. 5 C) and scattered positive
cells in TNF R1 KO mice (Fig. 5 D). The staining pattern
seen in KO liver is typical of early-stage carcinogenesis in-
Figure 5. Tumor formation after long-term CDE diet. Liver tissue from WT (A and C) and TNF R1 KO (B and D) mice after 36 wk of CDE diet.
Hematoxylin and eosin stain shows oval cells within a tumor in the liver of a WT mouse (A) and absence of tumor and oval cell proliferation but exten-
sive fat accumulation in a TNF R1 KO mouse (B). The tumor contains AFP-positive cells (C), but only a few cells stain for AFP in the liver of the KO
animal (D). Original magnifications: A, 3200, B–D, 3100.1815 Knight et al.
duced by a short-term CDE diet (50); it does not imply tu-
mor formation but does indicate that some preneoplastic
changes have occurred.
Discussion
Oval cell proliferation after chronic liver injury has been
well documented in a variety of models. The association of
oval cells with liver repopulation and carcinogenesis and
their ability to differentiate bipotentially suggest that oval
cells function as a liver progenitor cell compartment. Previ-
ous work has suggested roles for several cytokines in medi-
ating the growth of oval cells (27–33). However, a precise
understanding of signaling pathways involved in oval cell
proliferation is lacking. TNF-a has been shown to be a
growth factor for an oval cell line in vitro (39) and has also
been indirectly implicated in mediating oval cell prolifera-
tion in vivo (34). In this study, we sought to determine
whether TNF signaling is involved in the oval cell response
in mice.
Using a modification of the CDE diet protocol for in-
ducing oval cells in rats, we were able to induce oval cell
proliferation in mice within 1 wk. Analysis of TNF-a
mRNA levels showed that liver TNF rapidly increases after
commencement of the diet and is further elevated during
the initial stages of oval cell proliferation. Peak TNF levels
were detected after 2 wk of CDE feeding. Expression of
TNF in CDE liver was localized to oval and inflammatory
cells; expression was not detected in hepatocytes. The
early, sustained elevations in expression indicate that TNF
may play a role in both induction and maintenance of oval
cell proliferation in this model. In cultured oval cells, TNF
reinitiates growth in arrested cells and induces proliferation
through NF-kB activation (39). It remains to be established
whether NF-kB is a mediator of oval cell growth in vivo.
To directly evaluate the importance of TNF signaling in
the oval cell response in vivo, we used KO mice lacking
TNF R1 or TNF R2 and showed that signaling through
the type 1 but not the type 2 receptor is essential for opti-
mal oval cell response to the CDE diet. Compared with
WT and TNF R2 KO animals, TNF R1 KO mice had
fewer oval cells and a lower level of oval cell proliferation.
The impairment of the oval cell response in TNF R1 KO
mice was not a result of reduced damage caused by lack of
TNF R1 signaling, because similar levels of fat accumula-
tion, inflammatory cell infiltration, and serum ALT levels
were observed in TNF R1 KO and WT mice. In addition,
there was no difference between mortality of WT and
TNF R1 KO mice on the diet in either the short or long
term (data not shown), suggesting that the deficiency in
oval cell proliferation did not impair liver regeneration. It is
presumed that residual oval cell proliferation is sufficient to
maintain parenchyma in the TNF R1 KO animals. Fur-
thermore, although substantially impaired, liver regenera-
tion is detected in the KO mice (36). The CDE diet com-
promises the replicative capacity of hepatocytes. However,
some hepatocyte growth may still occur, and even in the
absence of TNF R1, hepatocyte regeneration may contrib-
ute to maintenance of liver function. Interestingly, an in-
crease in the ratio of liver/body weight was observed in
long-term TNF R1 KO mice. Untreated KO mice have
been reported to have normal liver weight (37), indicating
that administration of the CDE diet, in the long term, has
resulted in liver enlargement. The mechanisms underlying
this finding have not been addressed but may involve
proapoptotic signaling downstream of TNF R1. TNF R1
KO mice have impaired apoptosis in several models, in-
cluding acute hepatic injury (51, 52).
Current research suggests that TNF R1 is the dominant
TNF receptor (53, 54), and after partial hepatectomy, it is
this receptor, not TNF R2, that is appears to be active in
promoting hepatocyte growth (37). The signaling pathway
employed by regenerating hepatocytes proceeds via activa-
tion of NF-kB and IL-6 (36, 44). A similar mechanism is
suggested for oval cell–associated liver regeneration, be-
cause dexamethasone, which inhibits oval cell proliferation
(34), inhibits NF-kB nuclear translocation (35). However,
divergence of the pathways mediating oval cell and hepato-
cyte regeneration must exist, as oval cell proliferation does
not occur after partial hepatectomy. Evaluation of the oval
cell response in IL-6 KO mice suggests that IL-6 is in-
volved in oval cell proliferation induced by the CDE diet.
However, while oval cell proliferation is impaired in IL-6
KO mice, the extent of impairment is lesser in these mice
than in TNF R1 KO. This suggests that IL-6 is not the sole
downstream factor responsible for the TNF R1–mediated
effect. By contrast, after partial hepatectomy, IL-6 and
TNF R1 KO mice both have profound deficiencies in
hepatocyte replication (36, 44). This indicates that the fac-
tors mediating oval cell proliferation induced by the CDE
diet and hepatocyte replication after partial hepatectomy
may differ with respect to involvement of IL-6, although
both may require TNF R1 signaling. It is likely that the
optimal oval cell response involves several other cytokines,
which may include other members of the IL-6 family.
Oval cell proliferation is often seen in the early stages of
disease states that lead to cancer in humans (55–58) and ro-
dents (48, 59–62). This implicates the oval cell compart-
ment in the carcinogenic process. Based on this, it could be
hypothesized that the number of oval cells would positively
correlate with the likelihood of tumor formation. This
could explain the inhibition of tumor development in TNF
R1 KO mice. However, the possibility that TNF is itself
mediating tumor progression cannot be excluded. TNF has
been shown to direct differentiation of several cell types
(63–65). Absence of TNF has also been shown to impair
skin tumor formation (66). TNF enhances growth factor
mitogenicity (67) and may, therefore, affect transformation
of these cells. Thus, while the experiments showed that ab-
sence of TNF R1 reduces tumor formation, the exact role
of TNF signaling in the carcinogenic process is still unclear.
These studies, although they demonstrate a role for TNF
signaling in oval cell proliferation, also highlight the com-
plexity of the system mediating oval cell growth and differ-
entiation. Absence of TNF R1 is sufficient to reduce oval
cell numbers to approximately half of WT levels, but it1816 Tumor Necrosis Factor Signaling in Liver Carcinogenesis
does not completely abolish the oval cell response to CDE
feeding. This indicates that additional growth factors or sig-
naling pathways may supplement that of TNF R1 in oval
cell signaling. Other cytokines may be induced for the dif-
ferent phases of the oval cell response: infiltration, growth,
and differentiation. In this study, we have focused on the
growth phase and show that TNF R1 is important for oval
cell proliferation in this stage. By contrast, Matsusaka et al.
(30) show that stem cell factor, while promoting liver oval
cell infiltration, does not mediate the growth of these cells
within the liver parenchyma. The association of a proin-
flammatory response with oval cell proliferation indicates
that many cytokine systems may be activated during this
process and that multiple factors may be required for the
full oval cell response to liver damage. However, regardless
of additional factors, this study demonstrates the involve-
ment of TNF signaling in oval cell proliferation and car-
cinogenesis.
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